Public Health Laboratory Service Board

The Secretary of State for Defence in Her Britannic Majesty's Government

Biopharm (uk) Limited

E.i. Dupont De Nemours and Company

Merck Patent Gmbh

University of Bristol

Vernolix Limited

Generic Biologicals Limited

Public Health Laboratory Service, Center for Applied Microbiology &

Public Health Lab Svc Bd. University Coll.

Anthony Atkinson

Asgar Electricwala

Roy T Sawyer

Christopher Philip Price

Michael D Scawen

Christopher Powell-Jones

Peter M Hammond

Michael J Comer

Christopher J Bruton

Peter M Sutton

Joseph John Holbrook

Patrick Anthony Riley

Geoffrey B Cox

Gerard Voerman

Klaus Mosbach

Christopher R Lowe

John B Griffiths

Amy Latter

Peter A Edwardson

Jonathan P Murphy

William N Chia

Nils Von Sicard

Kevin John Bown

Helen M Wilks

John Karl Brehm

Stephen Phillip Chambers

Nigel Peter Minton

Graham Lloyd

Richard J Sharp

Alistair H Bingham

Stewart R Cambell

Anthony R Clarke

Paul G McClory

John R Ramsey

David A Small

Helen C Morris

Michael J Harvey

Epoxidised oil, epoxidised wax or epoxidised fatty acid ester recovered fromseeds provide topical medicament preparations which are effective in preventing and treating various different forms of skin diseases, skin lesions and wounds. These epoxidised oil, epoxidised wax or epoxidised fatty acid ester recovered fromseeds can also be bound to bio-available molecules, such as proteins, to modify the effect of the bio-available molecules when administered to the human body.

[object Object]

Disclosed is a method of detecting the presence in a sample of a polypeptide exogenously administered to a mammalian subject from whom the sample is obtained, and distinguishing between such an exogenously administered polypeptide and a naturally-occurring endogenous polypeptide present in the sample; the method comprising obtaining a sample from the subject; and subjecting the sample to analysis of fluorescence at a suitable wavelength; wherein the exogenously administered polypeptide is tagged with a greater or lesser amount of fluorescence activity, relative to the untagged endogenous polypeptide, at the wavelength(s) analyzed.

Detection of molecules in samples

A method for preventing the formation of platelet-rich clots or thrombus, and for deaggregating platelet-rich clots or thrombus, using hementin, a polypeptide derived from leech salivary glands. Hementin may be administered for this purpose in a pharmaceutically acceptable carrier or excipient, with or without additional anticoagulants such as hirudin, hirudin analogues, or an inhibitor of factor Xa.

Treatment of thrombotic events

A pharmaceutical composition for use in the prophylaxis or treatment of pathological conditions resulting from the presence of superoxide radicals, comprising a manganese-superoxide dismutase (MnSOD) enzyme and a pharmaceutically acceptable excipient. The MnSOD enzyme is in native form and has substantially the amino acid sequence of SEQ ID NO: 17 or SEQ ID NO: 29 and is free of pyrogens consisting of macromolecular substances native to Bacillus Stearothermophilus (BS) or Bacillus Caldotenax (BC). Processes for producing the novel pharmaceutical composition and a method for the prophylaxis or treatment of pathological conditions resulting from the presence of superoxide radicals utilizing the novel composition are also disclosed.

Pharmaceutical compositions containing superoxide dismutase from

Anti-thrombins

A method for the estimation of a salicylate in a sample is characterized by enzymatically converting the salicylate to a catechol by the action of a salicylate mono-oxygenase enzyme on the salicylate in the presence of a reduced pyridine nucleotide, reacting the catechol with a compound selected from compounds of formula I or amine or phenolic compounds of formulae II, III or IV ##STR1##

Assay of salicylates or reduced pyridine nucleotides

Protease inhibitor

Recombinant modified thermostable NAD-dependent dehydrogenases and

A method is provided for treating a viral infection in a subject by administering a surfactant and/or a steroid so as to produce a high concentration thereof in the systemic circulation. The method is particularly applicable to the treatment of HIV infections. The use of surfactants and/or steroids in the production of pharmaceutical compositions is described.

Method and composition for the treatment and prevention of viral

Fibrinolytic enzymes produced from established non-cancerous cell lines

A chromatographic packing useful for the separation of oligonucleotides is disclosed. The packing includes an insert porous support particle and a silane bonded phase comprising a weak anion exchange group in close proximity to at least one polar non-ionic group.

Chromatographic supports for separation of oligonucleotides

Chimeric plasmids

Affinity chromatography media are prepared by reacting mono or di-chloro triazine dyes with a solid support matrix containing free hydroxy or amino groups in the presence of an alkali metal hydroxide and an alkali metal salt. In the absence of cyanogen bromide activation, the linkage to the support is entirely via the triazine ring giving high and specific protein-binding capacity. Suitable support matrices include polymers and copolymers of agarose, dextrose, dextran and acrylamide with agarose being particularly preferred. Dye binding levels are much higher than those obtained in the presence of carbonates or bicarbonates. Mono-chlorotriazinyl dyes are bound at a pH which is preferably above 9.5. The reaction time is about 40-60 hours at room temperature, however this may be reduced if the reaction temperature is increased. Dichlorotriazinyl dyes are bound at pH 8 to 12.5 in a few hours at room temperature. The media may be used for the efficient and often highly specific purification of a wide variety of proteins, including enzymes and blood proteins.

Media for affinity chromatography

A process for the high pressure liquid affinity chromatographic separation of at least one biological or related substance from a mixture in which the contact, washing and eluting phases are performed on a binding material made from a ligand, containing at least one of the groups anthraquinone, phthalocyanine or aromatic azo, coupled to a matrix through a spacer arm, the binding material being so constructed that at least one biological or related substance is retained on the binding material during the contact and washing phases. In one preferred embodiment the ligand is a reactive dye, especially a triazinyl dye, the matrix is agarose or silica and the spacer arm is a substituted aminohexyl group. The chromatographic procedure is preferably performed at 100-3500 psi, at a flow rate of 0.5-2.0 ml/min. The choice of washing and eluting solutions depends on the material to be separated. However buffer solution to wash the column and a desorbing agent to elute the material are preferred. When the biological substance is an enzyme the desorbing agent is preferably an enzyme substrate, cofactor, inhibitor or analogue thereof. A binding material for use in the above HPLAC procedure is also provided. This is made from a ligand containing at least one of the groups anthraquinone, phthalocyanine or aromatic azo, coupled to a matrix through a spacer arm.

High pressure liquid affinity chromatography

A method for the estimation of an anilide in which the anilide is first hydrolyzed enzymatically to an aniline and then the quantity of the aniline produced is estimated spectrophotometrically preferably colorimetrically. The hydrolysis of the anilide may be catalyzed by any enzyme of the type, EC 3.5.1.13, known as aryl acylamidases. Preferably enzymes isolated from the cells of Pseudomonas fluorescens ATCC 39005 or Pseudomonas putida ATCC 39004 are employed. The aniline may be analyzed, for example, by conversion to an indamine, an indophenol or an indoaniline, followed by colorimetric analysis of the colored quinone-type compound produced. This conversion may take place in the presence of an oxidizing agent, such as a copper (II) salt, and/or a base, such as ammonia. A diagnostic kit to allow the routine use of the above method is also provided. In one embodiment of the kit, it comprises,

Method for the estimation of N-acylated primary aromatic amines

Growing community of inventors

Salisbury, United Kingdom

Anthony Atkinson